|
ECOG 1609 : A Phase III Randomized Study of Adjuvant Ipilimumab Anti-CTLA4 Therapy versus High-Dose Interferon á-2b for Resected High-Risk Melanoma
|
The purpose of this study is to compare the effects, good and/or bad, of ipilimumab with interferon alfa-2b on you and your melanoma to find out which is better. In this study, you will get either ipilimumab or the interferon alfa-2b. You will not get both. We plan to determine whether ipilimumab stops or delays your cancer from returning in comparison to interferon alfa-2b.
|
Principal Investigator(s):
Christopher G. Tretter, MD
For more information about this Research Study call 781-744-8027.
Study Coordinator(s):
Nevin Bhardwaj.
|